Evidence map›Paper›PMID 29683140›Full record

ArticleOpen access journal of biomedical engineering and its applications2018

Liquid Biopsy in the OMICS Era of Tumor Medicine.

Yi Jiang, Denong Wang

Open access · diamondAbstract read
PubMed Full text at PMC
In one paragraph

Article in Open access journal of biomedical engineering and its applications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yi JiangTumor Glycomics Laboratory, SRI International Biosciences Division, USA.
Denong WangTumor Glycomics Laboratory, SRI International Biosciences Division, USA.
SRI International · US

Funding

Immunogenic sugar moieties of prostate cancersU01CA128416 · NCI · STANFORD UNIVERSITY · PI WANG, DENONG · 2007 to 2011
$2.3M
B-1 B cell responses to oligomannosyl antigens of HIV-1R56AI118464 · NIAID · SRI INTERNATIONAL · PI WANG, DENONG · 2015 to 2015
$884k
IMMUNOGENIC SUGAR MOIETIES OF HCMVR21AI124068 · NIAID · SRI INTERNATIONAL · PI WANG, DENONG · 2017 to 2018
$521k
NCI NIH HHS U01 CA128416NIAID NIH HHS R21 AI124068NIAID NIH HHS R56 AI118464
6 · The paper itself

Abstract

Liquid biopsy uses noninvasive blood test to assess tumor heterogeneity and evolution in real time. It looks for tumor components in the blood circulation, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), to provide tumor-specific information. By detecting multiplex tumor biomarkers, including nucleic acids, proteins, carbohydrates, and other tumor-derived substances, liquid biopsy helps with early tumor diagnosis, tumor evolution monitoring, and prognosis prediction. With the development of high-throughput OMICS tools like carbohydrate microarray and high-speed fiber-optic array scanning technology (FAST scan), it is now practical to identify glycan markers of CTCs and cancer stem cells (CSCs), especially those that are cell-surface exposed and readily accessible for immune recognition and targeting. Potential of this class of biomarkers in tumor subtyping and targeted immunotherapy is yet to be explored.

Indexed as

Blood group precursorCancer stem cellsCarbohydrate microarrayCirculating tumor cellsCirculating tumor DNAGlycan markersGlycomicsLiquid biopsy

Identifiers

PMID29683140
PMCPMC5908475
OpenAlexW2900551733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.